Vertex Pharmaceuticals Logo

Email this page: News Release

Vertex Announces Plans to Enroll Additional Treatment Arm in Ongoing Phase 2 Combination Study of Telaprevir and VX-222 for the Treatment of People with Hepatitis C

For security reasons, registration is required before you can use this feature.
* Indicates required field